BERA (Brainstem Auditory Evoked Response) Testing — Cost, Top Hospitals & Success Rates | MyMedicPlus

Brainstem Evoked Response Audiometry (BERA), also called the Auditory Brainstem Response (ABR) or Brainstem Auditory Evoked Potential (BAEP), is an objective electrophysiological test that measures the electrical activity generated along the auditory pathway — from the cochlea through the auditory nerve to the inferior colliculus in the brainstem — in response to controlled acoustic stimuli. First described by Jewett and Williston in 1971, it remains a cornerstone of both diagnostic audiology and intraoperative neurophysiological monitoring.

The test is performed by attaching surface electrodes to the scalp (typically vertex and mastoid/earlobe) and presenting rapid click stimuli or frequency-specific tone bursts through insert earphones. Each stimulus generates a characteristic waveform consisting of seven peaks (Waves I–VII), known as the Jewett-Williston complex. Wave I reflects the distal cochlear nerve (CN VIII); Wave III corresponds to the cochlear nucleus in the pons; Wave V — the most robust and clinically important — arises at the level of the lateral lemniscus/inferior colliculus. Absolute latencies, interpeak latencies (I–III, III–V, and I–V intervals), and amplitude ratios provide critical diagnostic information.

BERA is entirely objective: it does not require any voluntary response from the patient, making it the gold standard for hearing threshold estimation in newborns, infants, and individuals who cannot cooperate with conventional behavioural audiometry. Its sensitivity for detecting retrocochlear pathology — particularly vestibular schwannoma (acoustic neuroma) — rivals that of gadolinium-enhanced MRI for tumours affecting neural conduction velocity.

Two principal technical variants are used clinically. Diagnostic ABR involves manually interpreting waveforms across a range of stimulus intensities to estimate hearing thresholds and characterise auditory pathway function. Automated ABR (aABR) uses an algorithm to generate a "pass" or "refer" outcome and is the preferred tool within national neonatal hearing screening programmes such as the NHS NHSP pathway in the UK.

BERA has a broad range of diagnostic and monitoring applications across audiology and neurology:

• Neonatal and infant hearing screening: Automated ABR (aABR) is used in national neonatal hearing screening programmes to identify permanent childhood hearing impairment (PCHI) from birth. In the UK NHS NHSP pathway, babies who "refer" on automated otoacoustic emissions (AOAE) undergo aABR, with a second aABR offered if the first result is a refer. Diagnostic ABR is then used for infants who continue to refer, providing frequency-specific threshold information.
• Sensorineural hearing loss estimation: Tone-burst ABR enables frequency-specific threshold estimation at 500 Hz, 1 kHz, 2 kHz, and 4 kHz with an accuracy of ±10 dB relative to behavioural pure-tone thresholds. This is critical for fitting hearing aids and cochlear implant candidacy assessment in children too young for behavioural testing.
• Retrocochlear pathology: Prolonged absolute latencies of Waves I, III, and V, and especially prolonged I–III and I–V interpeak latencies, are hallmark findings in vestibular schwannoma (acoustic neuroma), cerebellopontine angle tumours, and multiple sclerosis affecting the auditory pathways. An I–V interpeak latency exceeding 4.4 ms is strongly suggestive of retrocochlear dysfunction.
• Brainstem pathology: Wave absence, latency prolongation, or amplitude reduction can indicate brainstem gliomas, demyelinating disease (MS), vascular lesions, or central auditory processing disorders. The ABR is a valuable biomarker in neurological conditions affecting the pons and midbrain.
• Meniere's disease and endolymph assessment: Electrocochleography (ECochG), a variant performed with a transtympanic or extratympanic electrode close to the cochlea, measures the summating potential (SP) and action potential (AP). An SP/AP ratio exceeding 0.45 supports the diagnosis of endolymphatic hydrops (Meniere's disease).
• Intraoperative neurophysiological monitoring: Continuous ABR monitoring is essential during acoustic neuroma (vestibular schwannoma) surgery, posterior fossa surgery, and microvascular decompression to provide real-time warning of cochlear nerve compromise, allowing the surgeon to adjust technique and reduce the risk of postoperative hearing loss.
• Auditory neuropathy spectrum disorder (ANSD): ANSD is characterised by absent or severely abnormal ABR waveforms in the presence of normal cochlear outer hair cell function (present OAEs). Identifying this condition is critical because it changes audiological management significantly.

BERA is appropriate across all age groups, from premature neonates to elderly adults, because it requires no active participation from the patient. Key eligibility considerations include:

• Neonates and infants (aABR): All newborns are eligible. In the NHS NHSP, babies born in hospital are screened before discharge; babies born at home are screened within the first few weeks of life. Automated ABR is performed during natural sleep after a feed.
• Children unable to cooperate with behavioural audiometry: Children under approximately 6 months corrected age, children with developmental delays, autism spectrum disorder, or any condition preventing reliable behavioural responses are ideal candidates for diagnostic ABR. Sedation (chloral hydrate, melatonin) or general anaesthesia (GA) may be required for children aged approximately 6 months to 4 years who cannot sleep naturally during the test.
• Adults with suspected retrocochlear pathology: Any adult presenting with unilateral or asymmetric sensorineural hearing loss, unilateral tinnitus, sudden sensorineural hearing loss, or vestibular symptoms should be evaluated with ABR (or gadolinium-enhanced MRI) to exclude vestibular schwannoma.
• Pre-surgical assessment: ABR is indicated before acoustic neuroma surgery, cochlear implantation, and certain posterior fossa procedures to establish baseline auditory function.
• Medicolegal and occupational hearing assessment: When a reliable behavioural audiogram cannot be obtained, ABR provides an objective threshold estimate for legal, disability, or workers' compensation purposes.
• Contraindications: There are no absolute contraindications to diagnostic ABR. Sedation or GA carries its own risk-benefit consideration in young infants. Patients with significant scalp skin conditions at electrode sites may require alternative electrode placement.

Several technically distinct variants of ABR exist, each with specific clinical indications:

• Click-evoked ABR (standard diagnostic): The most widely used modality. Broad-spectrum click stimuli (approximately 90 dB nHL initial intensity, decremented in 10–20 dB steps to threshold) elicit all seven Jewett-Williston waves. Wave V threshold is recorded as the lowest stimulus level at which Wave V is reliably identifiable. This gives an estimate weighted towards mid-to-high frequency hearing (2–4 kHz). Latency-intensity functions assess for recruitment (cochlear loss) versus latency prolongation (retrocochlear pattern).
• Tone-burst ABR (frequency-specific ABR): Short tone bursts (typically windowed with Blackman or Gaussian envelopes) at 500 Hz, 1 kHz, 2 kHz, and 4 kHz enable frequency-specific threshold estimation. Notch-noise masking (derived-band ABR or high-pass noise masking) improves frequency specificity. This technique is essential for audiogram construction in non-cooperative children and underpins hearing aid fitting prescriptions.
• Automated ABR (aABR) for neonatal screening: Devices such as ALGO (Natus) or MB11 BERAphone use pre-set stimulus parameters and proprietary pass/refer algorithms (cross-correlation template matching) at 35 dB nHL to generate a result without manual waveform interpretation. The automated nature eliminates inter-examiner variability and allows use by trained healthcare assistants.
• Electrocochleography (ECochG): A transtympanic (needle through tympanic membrane under topical or local anaesthesia) or extratympanic electrode is placed close to the cochlea to record the cochlear microphonic (CM), summating potential (SP), and whole-nerve action potential (AP). The SP/AP amplitude ratio is the primary diagnostic measure for endolymphatic hydrops; a ratio above 0.45 at click stimulation strongly supports Meniere's disease. ECochG also provides the clearest Wave I in patients where scalp-recorded Wave I is absent, facilitating I–V interpeak latency calculation.
• Intraoperative ABR monitoring: Continuous real-time ABR recording is conducted with surgically placed or miniature insert earphones during posterior fossa and acoustic neuroma surgery. Alarm criteria typically include a Wave V latency shift of more than 1 ms or an amplitude reduction exceeding 50% from baseline, prompting surgical team alert. Simultaneous electromyographic (EMG) facial nerve monitoring is standard in these procedures.
• Auditory steady-state response (ASSR): While technically distinct from ABR, ASSR is a related technique using amplitude/frequency-modulated tones and spectral analysis to provide objective frequency-specific thresholds, particularly at high stimulus levels, complementing tone-burst ABR in paediatric audiological assessment.

BERA offers several advantages that make it indispensable in modern audiology and neuro-otology:

• Objective and non-invasive: Unlike behavioural audiometry, BERA does not depend on patient cooperation or subjective response. The test is entirely passive — electrodes record naturally occurring neural responses — making it uniquely reliable in populations who cannot participate in conventional testing.
• Early detection of hearing loss: Universal neonatal hearing screening using aABR enables identification and intervention for permanent childhood hearing impairment within the first weeks of life. Early fitting of hearing aids or cochlear implants, ideally before 6 months of age, critically improves language and developmental outcomes.
• Precise anatomical localisation: By analysing absolute latencies and interpeak intervals, ABR can localise pathology to specific segments of the auditory pathway — cochlea, cochlear nerve, pons, or midbrain — providing information unavailable from behavioural audiometry alone.
• High sensitivity for acoustic neuroma: ABR has a sensitivity of approximately 92–95% for acoustic neuromas larger than 1 cm, identifying abnormal interpeak latencies or Wave V absence before symptoms are severe. Sensitivity is lower for intracanalicular tumours, where gadolinium-enhanced MRI remains the definitive investigation.
• Intraoperative preservation of function: Real-time ABR monitoring during acoustic neuroma surgery provides continuous feedback that has been shown to reduce rates of postoperative profound hearing loss, supporting hearing-preservation surgical approaches in eligible patients.
• Diagnostic efficiency: A single diagnostic ABR session can simultaneously assess hearing threshold, evaluate retrocochlear function, characterise auditory neuropathy, and provide baseline data for surgical planning or medical management.
• No radiation exposure: BERA involves only low-intensity acoustic stimuli and surface electrodes — there is no ionising radiation, contrast agent, or magnetic field exposure, making it safe for repeated use across all age groups.

BERA is a very safe procedure, but clinicians and families should be aware of certain limitations and procedural considerations:

• Sedation and general anaesthesia risk in infants: Infants and young children who cannot sustain natural sleep during the test may require sedation (chloral hydrate 50–75 mg/kg, or melatonin) or general anaesthesia. Although GA is rare for BERA alone, it carries inherent anaesthetic risks (respiratory depression, allergy) that must be weighed against diagnostic benefit, particularly in neonates with comorbidities.
• False positive and false negative rates in neonatal screening: The aABR refer rate in well-baby populations is approximately 0.5–1.5%, the majority of which are false positives (e.g., due to vernix in the ear canal, transient middle ear fluid, or test conditions). Conversely, aABR may not detect mild hearing loss (25–35 dB HL) because the screening level is set at 35 dB nHL. Mild permanent childhood hearing impairment can therefore be missed.
• Frequency specificity limitations of click ABR: Standard click-evoked ABR reflects predominantly high-frequency (2–4 kHz) auditory function. Low-frequency sensorineural hearing loss may not be accurately represented without tone-burst ABR at 500 Hz with appropriate masking.
• Muscle artefact interference: Myogenic artefacts from patient movement or muscle tension can obscure waveforms, particularly in unsedated children or anxious adults. Adequate signal averaging (1,500–2,000 sweeps) and artefact rejection are essential to ensure waveform reliability.
• Technical expertise dependence: Accurate interpretation of diagnostic ABR waveforms requires specialist audiological training. Mis-identification of waves, failure to account for high-frequency hearing loss when interpreting latencies, or incorrect electrode placement can lead to diagnostic error.
• Limited sensitivity for small tumours: ABR sensitivity for acoustic neuromas smaller than 1 cm (particularly purely intracanalicular tumours) is approximately 60–75%. Gadolinium-enhanced MRI of the internal auditory meati remains the definitive investigation when clinical suspicion is high despite a normal ABR.
• ECochG-specific risks: Transtympanic electrocochleography involves needle puncture of the tympanic membrane under local anaesthesia. Risks include tympanic membrane perforation (usually heals spontaneously), transient discomfort, and very rarely infection.

The follow-up pathway after BERA depends on the clinical indication and test findings:

• Neonatal hearing screening pathway (NHSP): A "refer" result on aABR leads to a repeat aABR (or repeat AOAE and aABR in a sequential programme) before 4 weeks of corrected age. Persistent refer on both ears leads to referral for diagnostic ABR and full audiological assessment by 3 months of corrected age. Confirmed bilateral moderate-to-profound SHNL triggers referral to cochlear implant centres; unilateral or mild losses receive hearing aid fitting.
• Retrocochlear findings: An abnormal ABR with prolonged I–V interpeak latency or absent Wave V in an adult with asymmetric hearing loss or tinnitus warrants gadolinium-enhanced MRI of the internal auditory meati and cerebellopontine angles to definitively exclude vestibular schwannoma. Confirmed tumours are managed by observation (surveillance MRI), stereotactic radiosurgery (Gamma Knife, CyberKnife), or microsurgical resection depending on size, symptoms, and patient preference.
• Meniere's disease (ECochG follow-up): An elevated SP/AP ratio supports diagnostic confidence but does not change the treatment pathway; management of confirmed Meniere's disease proceeds with dietary sodium restriction, betahistine, intratympanic steroids or gentamicin, or endolymphatic sac surgery, guided by symptom severity.
• Post-surgical monitoring: Following acoustic neuroma surgery with intraoperative ABR monitoring, postoperative hearing thresholds are assessed with standard audiometry at 4–6 weeks. Patients with preserved hearing receive audiological follow-up and may benefit from hearing augmentation if thresholds have shifted.
• Paediatric audiology rehabilitation: Children diagnosed with PCHI via ABR are enrolled in audiological habilitation programmes encompassing hearing aid fitting, cochlear implant evaluation, speech and language therapy, and educational support according to national guidelines (e.g., NICE CG98).
• Repeat testing: ABR may be repeated to monitor disease progression, evaluate response to treatment, or provide updated threshold data for hearing aid reprogramming. There are no restrictions on the frequency of testing.

The cost of BERA varies considerably based on the type of test, clinical setting, country, and whether sedation or general anaesthesia is required:

• Setting and country: In countries with publicly funded neonatal screening programmes (UK NHS, Australia, Canada), aABR neonatal screening is provided free at the point of care. Diagnostic ABR for older children or adults is covered under most national health insurance systems when clinically indicated. In the United States, diagnostic ABR may cost between USD 300 and USD 800 depending on provider and payer. In India, ABR testing at accredited ENT and audiology centres typically costs INR 2,000–6,000.
• Type of test: Automated aABR (neonatal screening) is the least expensive modality. Full diagnostic ABR with tone-burst thresholds at multiple frequencies is more resource-intensive. ECochG adds procedure time and specialised electrode costs. Intraoperative ABR monitoring is charged as a surgical neuromonitoring service, typically per-hour.
• Sedation or general anaesthesia: The largest cost driver for paediatric ABR is the anaesthesia service. GA-assisted ABR in a day surgery setting adds anaesthesiologist fees and operating room costs, which can add USD 500–2,500 in high-income countries.
• Hospital type and accreditation: Tertiary academic medical centres and paediatric hospitals typically offer the full spectrum of ABR variants including ECochG and intraoperative monitoring. Community audiology clinics may offer only click-ABR screening services.
• Medical tourism considerations: Patients travelling from countries with long waiting lists or high private costs can access high-quality diagnostic ABR at significant savings in India, Thailand, or Malaysia. JCI-accredited centres offer equipment and audiologist competency standards comparable to those in Western Europe and North America.

BERA is often used alongside or instead of the following audiological and neuroradiological investigations:

• Otoacoustic emissions (OAE — TEOAE and DPOAE): OAEs test outer hair cell function in the cochlea and are faster and less expensive than ABR. They are the first-line neonatal screening tool in many programmes (AOAE). However, OAEs are absent in middle ear pathology (even with normal cochleae) and provide no information about the auditory nerve or brainstem. OAE cannot detect auditory neuropathy spectrum disorder.
• Pure-tone audiometry (PTA): The gold-standard behavioural hearing test for cooperative adults and older children. PTA provides a complete frequency-specific audiogram (125 Hz–8 kHz) for both air and bone conduction. It requires patient reliability and cannot be used in infants or non-cooperative individuals.
• Visual reinforcement audiometry (VRA): Used in children aged approximately 6 months to 2.5 years, VRA conditions behavioural responses to sounds using visual reinforcers (animated toys). It provides frequency-specific thresholds but requires cooperation and a trained audiologist-team paediatric protocol.
• Auditory steady-state response (ASSR): A complementary electrophysiological technique particularly useful for estimating thresholds at multiple frequencies simultaneously and at high stimulus intensities where tone-burst ABR Wave V is difficult to identify. ASSR is increasingly combined with tone-burst ABR in paediatric audiological assessment.
• Gadolinium-enhanced MRI of internal auditory meati: The definitive investigation for retrocochlear pathology, with near-100% sensitivity for vestibular schwannoma of any size, including intracanalicular tumours where ABR sensitivity is limited. MRI is more costly and less accessible than ABR; ABR therefore serves as a cost-effective screening tool before MRI in populations with lower pre-test probability.
• Cortical auditory evoked potentials (CAEP/P1-N1-P2): Longer-latency potentials arising from the auditory cortex, used in central auditory processing disorder assessment and in monitoring cortical maturation in children fitted with hearing aids or cochlear implants.